Full text is available at the source.
The novel DYRK1A inhibitor KVN93 regulates cognitive function, amyloid-beta pathology, and neuroinflammation
The new DYRK1A blocker KVN93 may improve thinking, reduce amyloid-beta buildup, and lower brain inflammation
AI simplified
Abstract
KVN93 treatment in 5x FAD mice significantly improved long-term memory and reduced Aβ plaque levels.
- KVN93 enhanced dendritic synaptic function, which is associated with improved long-term memory.
- Aβ plaque levels were significantly reduced by KVN93 through the regulation of Aβ degradation enzymes neprilysin and insulin-degrading enzyme.
- Microglial and astrocyte activation induced by Aβ was significantly suppressed in KVN93-treated 5x FAD mice.
- KVN93 altered neuroinflammation in microglial cells but not in primary astrocytes by modulating signaling pathways.
- In wild-type mice, KVN93 treatment reduced activation of microglia and astrocytes following LPS injection.
AI simplified